MX2010001512A - Nuevo procedimiento de preparacion. - Google Patents

Nuevo procedimiento de preparacion.

Info

Publication number
MX2010001512A
MX2010001512A MX2010001512A MX2010001512A MX2010001512A MX 2010001512 A MX2010001512 A MX 2010001512A MX 2010001512 A MX2010001512 A MX 2010001512A MX 2010001512 A MX2010001512 A MX 2010001512A MX 2010001512 A MX2010001512 A MX 2010001512A
Authority
MX
Mexico
Prior art keywords
preparation process
novel preparation
mentioned
general formula
description
Prior art date
Application number
MX2010001512A
Other languages
English (en)
Inventor
Rolf Schmid
Juergen Schnaubelt
Thomas Krueger
Emanuel Stehle
Thomas Fachinger
Michael Konrad
Joern Merten
Carsten Reichel
Svenja Renner
Bianca Werner
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2010001512A publication Critical patent/MX2010001512A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Es objeto de la presente invención un procedimiento para preparar compuestos de la fórmula general I (ver fórmula I) en la que R1 y R2 se definen como se menciona en la descripción, sus sales y solvatos de tolerancia farmacéutica, que se pueden obtener a partir de compuestos de la fórmula general II (ver fórmula II) en la que R1 se define como se menciona en la descripción.
MX2010001512A 2007-08-13 2008-08-12 Nuevo procedimiento de preparacion. MX2010001512A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007038251A DE102007038251A1 (de) 2007-08-13 2007-08-13 Neues Herstellverfahren
PCT/EP2008/060560 WO2009021943A2 (de) 2007-08-13 2008-08-12 Neues herstellverfahren

Publications (1)

Publication Number Publication Date
MX2010001512A true MX2010001512A (es) 2010-03-10

Family

ID=39874112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001512A MX2010001512A (es) 2007-08-13 2008-08-12 Nuevo procedimiento de preparacion.

Country Status (16)

Country Link
US (1) US8288531B2 (es)
EP (1) EP2188275A2 (es)
JP (1) JP2010535838A (es)
KR (1) KR20100052531A (es)
CN (1) CN101821258A (es)
AR (1) AR068807A1 (es)
AU (1) AU2008288430A1 (es)
BR (1) BRPI0815419A2 (es)
CA (1) CA2696257A1 (es)
CL (1) CL2008002377A1 (es)
DE (1) DE102007038251A1 (es)
MX (1) MX2010001512A (es)
PE (1) PE20090515A1 (es)
TW (1) TW200918518A (es)
UY (1) UY31282A1 (es)
WO (1) WO2009021943A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
CN103601722B (zh) * 2013-09-13 2016-03-02 南京华威医药科技开发有限公司 新型抗肿瘤化合物
CN105777615A (zh) * 2016-04-07 2016-07-20 戊言医药科技（上海）有限公司 4-吗啉代哌啶的制备方法
CN109153686B (zh) 2016-05-07 2021-04-30 上海复尚慧创医药研究有限公司 一类蛋白激酶抑制剂
EP3470394B1 (en) * 2016-06-09 2022-01-26 Yuki Gosei Kogyo Co., Ltd. Method for preparing 4-(piperidin-4-yl)morpholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904421D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New compounds
MXPA05002115A (es) * 2002-08-30 2005-05-23 Hoffmann La Roche Compuestos novedosos de 2-ariltiazol como agonistas de pparalfa y ppargama.
EP1619187A1 (de) 2004-07-23 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von 3-(4-Piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren

Also Published As

Publication number Publication date
DE102007038251A1 (de) 2009-02-19
EP2188275A2 (de) 2010-05-26
US8288531B2 (en) 2012-10-16
CN101821258A (zh) 2010-09-01
WO2009021943A3 (de) 2009-04-30
UY31282A1 (es) 2009-03-31
TW200918518A (en) 2009-05-01
WO2009021943A2 (de) 2009-02-19
BRPI0815419A2 (pt) 2015-02-03
AU2008288430A1 (en) 2009-02-19
PE20090515A1 (es) 2009-05-28
JP2010535838A (ja) 2010-11-25
AR068807A1 (es) 2009-12-09
CL2008002377A1 (es) 2009-10-23
CA2696257A1 (en) 2009-02-19
US20110087021A1 (en) 2011-04-14
KR20100052531A (ko) 2010-05-19

Similar Documents

Publication Publication Date Title
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
MX2009014104A (es) Metodos para sintetizar cinacalcet y sales del mismo.
NZ590334A (en) ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
TW200833675A (en) Nicotinamide derivatives
MX347841B (es) Procedimiento para preparar derivados de antranilamida sustituidos con tetrazoles y polimorfos cristalinos novedosos de estos derivados.
IN2012DN03182A (es)
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY152281A (en) 4-pyrimidinesulfamide derivative
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2011007978A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2010009860A (es) Sintesis total de salinosporamida a y sus analogos.
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2010003213A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2010001512A (es) Nuevo procedimiento de preparacion.
MX2012002818A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
IN2012DN01292A (es)
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
WO2009075516A3 (en) Process for preparing pantoprazole sodium sesquihydrate
GEP20125460B (en) New process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts
WO2008059513A3 (en) Compounds suitable as modulators of hdl
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MY150428A (en) Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal